ClinicalTrials.gg
TerminatedNCT06508489Updated Oct 19, 2026Results posted

A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies

A Phase 1/2 interventional study of SAR443579 and venetoclax in Acute Myeloid Leukemia, sponsored by Sanofi. Terminated at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Early discontinuation based on strategic sponsor decision not driven by any safety concerns
Updated Oct 19, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Leukemia, Myeloid, Acute by Sanofi — none open to participants now, none under way, none of them phase 3. Leukemia, Myeloid, Acute · Sanofi.

Enrollment
12th of 15
7 · median 40
Started
2024
the only one that year
Phase 1/2
3 of 16
none open now
Registered
16th of 16
by date

Among the 16 studies in Leukemia, Myeloid, Acute by Sanofi, this one is the 12th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 1/2, and was the 16th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

None of the 16 studies in Leukemia, Myeloid, Acute by Sanofi is open now. The open studies under Leukemia, Myeloid, Acute, anywhere →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Leukemia, Myeloid, Acute by Sanofi as a file.
02

Study summary

This was a parallel, Phase 1/Phase 2, randomized, open label, multi-cohort, multi-center study assessing the safety, tolerability and preliminary efficacy of SAR443579 with different agents for treatment in adolescent and/or adult participants with CD123 expressing hematological malignancies.

This protocol was structured as a master protocol (containing common protocol elements). Individual sub-studies would explore SAR443579 with combination partners, which might include approved or investigational agents.

Experimental sub-studies would be tested through 3 parts:

Part 1: dose finding (such as dose escalation/ safety run-in). Part 2: dose optimization (when applicable). Part 3: dose expansion. In each sub-study, a dose escalation would identify preliminary recommended dose for expansion (pRDE) of SAR443579 and its respective combination partner. Following the determination of the preliminary RDE, additional participants would be enrolled in the dose expansion part, or if dose optimization needs to be further evaluated, additional participants would be enrolled in the "dose optimization/expansion" part. Dose optimization and dose expansion part could involve randomization depending on specific sub-study design.

Study consisted of a screening period, treatment period, and follow-up period. Participants would receive study treatment until documented disease progression, unacceptable adverse events, participant's decision to stop study treatment, or completion of the maximum cycles allowed in the sub-studies, or the participant met other criteria for discontinuation per study protocol (whichever occurred first).

Read the detailed description

Substudy 01:

Title: A Phase 1/Phase 2, open-label, multi-center study, assessing the safety, tolerability and the preliminary efficacy of SAR443579 administered in combination with azacitidine + venetoclax in adult participants with CD123 expressing newly diagnosed Acute Myeloid Leukemia (ND-AML) that are ineligible for intensive chemotherapy

Short title: A study to investigate natural killer cell engager (SAR443579) in combination with azacitidine + venetoclax in adult participants with newly diagnosed acute myeloid leukemia

The expected duration of the study for a participant was approximately about 2.5 years. The study duration includes a screening period, an induction and maintenance. After the end of study treatment participants would enter the follow-up period for up to 2 years.

Planned number of participants:

22 participants planned to be screened, 8 being adults and 14 being elderly; 9-18 participants planned to be enrolled (dose escalation part)

Enrollment would be paused upon completion of Part 1: Dose Escalation. The available data would be reviewed and the recommended doses and schedule for optimization would be selected by the study board. Enrollment in the Part 2: Dose optimization and Part 3: Dose expansion would be provided in a future protocol amendment.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • AML
04

Who can participate

The criteria were revised on the registry on Oct 19, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Participants with CD123-expressing hematological neoplasm per the 5th edition of the WHO Classification of Hematolymphoid Tumors.

Substudy 01:

  • Participants must be ≥18 years of age
  • Confirmed diagnosis of Acute Myeloid Leukemia
  • Ineligible for intensive chemotherapy. Ineligible for intensive chemotherapy was defined by the following criteria:

A) ≥ 75 years of age, OR

B) 18 to 74 years of age and meeting one or more of the following:

  1. (ECOG) performance status 2-3.
  2. Cardiac history of congestive heart failure (CHF) requiring treatment or (LVEF) ≤50% or symptomatic coronary heart disease confirmed by coronarography or cardiac imaging.
  3. Diffusing capacity of the lungs for carbon monoxide (DLCO) ≤65% or (FEV1) ≤65%.
  4. ≥30 to \<45 mL/min calculated by modification of diet in renal disease () formula.
  5. Moderate hepatic impairment with total >1.5 to ≤3.0x (ULN).

    • Participant with an Eastern Cooperative Oncology Group (ECOG) performance status as follows:

a) 0 to 2 for participants ≥75 years of age or b) 0 to 3 for participants 18 to 74 years of age.

  • For participants ≥75 years of age, adequate renal function demonstrated by a creatinine clearance ≥30 mL/min, calculated by modification of diet in renal disease (MDRD)
  • Participant with adequate liver function demonstrated by the following:

    1. For participants 18 to 74 years of age, (AST) ≤3.0 × ULN, alanine aminotransferase (ALT) ≤3.0 × ULN and bilirubin ≤3.0 × ULN, unless considered due to leukemic organ involvement ˂5 × ULN.
    2. For participants ≥75 years of age, aspartate aminotransferase (AST) ≤3.0 × ULN, alanine aminotransferase (ALT) ≤3.0 × ULN and bilirubin ≤1.5 × ULN, unless considered due to leukemic organ involvement ˂5 × ULN.

Exclusion criteria

Exclusion Criteria:

  • Any , uncontrolled medical conditions (including any serious active systemic infection that was not controlled)
  • Known second either progressing or requiring active treatment within the last 3 years prior to first IMP administration
  • Known acquired immunodeficiency syndrome (AIDS-related illnesses) or disease requiring antiretroviral treatment, or having active or C infection, or SARS-CoV-2 infection. With exception for:

    1. HBV as determined by positive test for hepatitis B surface antigen (HBsAg) and/or HBV DNA. Participant who tested positive for anti-hepatitis B core (HBc) antigen IgG (with or without testing positive for anti-HBs), but tested negative for HBsAg and HBV DNA, was eligible.
    2. A participant who tested positive for anti- antibodies and had undetectable HCV RNA without receiving antiviral treatment for HCV was eligible.
  • Active, known, or suspected clinically significant disease that had required systemic treatment in the past 2 years prior to first IMP administration, except controlled by replacement therapy (eg, thyroxine, insulin, or physiologic replacement therapy for adrenal or pituitary insufficiency, etc)
  • Predicted ≤3 months.
  • Medical conditions requiring treatment with medications with narrow therapeutic index that were substrates of CYP enzymes and that could not be closely monitored to allow for dose adjustment.
  • Ongoing adverse event of [Version 5.0] Grade 2 or greater severity cause by any prior anti-cancer therapy

Substudy 01:

  • Patient with Acute Promyelocytic Leukemia (APL)
  • Known active central nervous system involvement with AML at the time of enrollment as evidenced by cytology or pathology
  • Cardiovascular disease of (NYHA) Class ≥2.
  • Malabsorption syndrome or other condition that precludes enteral route of administration
  • A baseline of (using the Fridericia correction calculation) >470 msec.
  • Participant had received treatment with at least one of the following:

    1. A hypomethylating agent, venetoclax and/or chemo therapeutic agent for AML other than hydroxyurea used for disease control prior to the initiation of study therapy.
    2. Experimental therapies for AML.
    3. Concomitant medications of strong and moderate inducers within 7 days prior to the initiation of study treatment.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Substudy 01: SAR443579 + azacitidine + venetoclax

    Part 1: Safety run-in: SAR443579 treatment will begin with an identified starting dose. Safety run-in will proceed according to the incidence of DLTs.

    Biological: SAR443579 · Drug: venetoclax · Drug: azacitidine

Interventions

  • BiologicalSAR443579

    Pharmaceutical form: Powder for solution for infusion Route of administration: intravenous infusion

  • Pharmaceutical form :Film coated tablet Route of administration: oral

    Also known as: VENCLYXTO / VENCLEXTA

  • Pharmaceutical form: Lyophilized powder for suspension for injection Route of administration: intravenous or subcutaneous

06

What researchers measure

Primary outcomes

  1. Sub-study 1: Part 1: Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)

    DLT=any of the following events during Cycle 1 (first 28 days) using NCI CTCAE v5.0 or ASTCT criteria, whether related or not to study treatment in absence of clear evidence to the contrary, and if not related to disease progression. Hematologic DLTs :toxicities, bone marrow hypocellularity, decreased neutrophils, febrile neutropenia, decreased platelets, anemia (all Grade 4) and Grade 3 thrombocytopenia. Non-hematologic DLTs: organ toxicities or infusion reaction (both Grade 4), Grade 3 infusion reaction lasting \>24 hours, Hy's law cases, Grade 3-4 infection, Grade 3 electrolyte abnormalities or transaminitis elevation, Grade \>=3 toxicities except alopecia, Grade 3 fatigue, asthenia, fever, anorexia, constipation, nausea, vomiting, diarrhea, infection, bleeding, Grade 3 cytokine release syndrome or laboratory abnormalities, Grade 3 or 4 tumor lysis syndrome. Any treatment related toxicity causing \>2-week delay in recovery to baseline/Grade \<=1 or requiring dose reduction/withdrawal.

    Time frame: From Day 1 to Day 28 of Cycle 1 (each cycle was 28 days)

  2. Sub-study 1: Part 2: Dose Optimization: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (SAEs) and Treatment-emergent Adverse Events of Special Interest (AESIs)

    An AE was any untoward medical occurrence in participant or clinical study participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was any AE, that at any dose: resulted in death, was life-threatening, required inpatient hospitalization/prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was a medically important event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. The TEAEs were defined as AEs that developed, worsened or became serious after the first administration of study treatment up to 30 days after the last administration of study treatment.

    Time frame: AEs were planned to be collected from first dose of study treatment (Day 1) up to 30 days post last dose of study treatment

  3. Sub-study 1: Part 2: Dose Optimization: Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Hematology Parameters

    Blood samples were planned to be collected to determine the PCSA in hematology.

    Time frame: Planned to be collected from first dose of study treatment (Day 1) up to 30 days post last dose of study treatment

  4. Sub-study 1: Part 2: Dose Optimization: Number of Participants With Potentially Clinically Significant Abnormalities in Clinical Chemistry Parameters

    Blood samples were planned to be collected to determine the PCSA in clinical chemistry.

    Time frame: Planned to be collected from first dose of study treatment (Day 1) up to 30 days post last dose of study treatment

  5. Sub-study 1: Part 2: Dose Optimization: Complete Remission (CR) Rate

    The CR rate was defined as percentage of participants who had a CR determined by the Investigator according to 2022European Leukemia Net (ELN) recommendations for diagnosis and management of AML.

    Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenancecycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause,whichever occurred first

  6. Sub-study 1: Part 3: Dose Expansion: Complete Remission (CR) Rate

    The CR rate was defined as percentage of participants who had a CR determined by the Investigator according to 2022 European Leukemia Net (ELN) recommendations for diagnosis and management of AML.

    Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

Secondary outcomes

  1. Sub-study 1: Part 1: Dose Escalation and Part 3: Dose Expansion: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TE Serious Adverse Events (TESAEs) and TE Adverse Events of Special Interest (TEAESIs)

    An AE was any untoward medical occurrence in participant or clinical study participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was any AE, that at any dose: resulted in death, was life-threatening, required inpatient hospitalization/prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was a medically important event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. TEAEs: AEs that developed, worsened/became serious after first administration of study treatment up to 30 days after last administration of study treatment.

    Time frame: From the first dose of study drug administration (Day 1) up to early termination of the study, maximum treatment duration was 31.3 weeks

  2. Sub-study 1: Part 3: Dose Expansion: Percentage of Participants With Minimal Residual Disease

    The minimal residual disease rate was defined as the percentage of participants with minimal residual disease as defined by 2022 ELN in participants achieving a CR, CR with partial hematologic recovery (CRh) or CR with incomplete hematologic recovery (CRi).

    Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

  3. Sub-study 1: All 3 Parts: Concentrations Observed at the End of Dosing Period During Repeated Administration (Ctrough) of SAR443579

    Blood samples were collected just before treatment administration during repeated dosing to determine the Ctrough of SAR443579 during dose escalation part. Participants missed few scheduled site visits for sample collection and only participants with data collected at specified timepoints are reported.

    Time frame: Part 1:Dose escalation (dose levels 1 and 2): Pre-dose: At Days 1, 8, 15 and 22 of Cycle 1 and Days 8, 15, 22 and 28 of Cycle 2 (each cycle was 28 days)

  4. Sub-study 1: All 3 Parts: Maximum Plasma Concentration Observed (Cmax) of Venetoclax

    Blood samples were collected at specified timepoints to determine Cmax of venetoclax during dose escalation part. Participants missed few scheduled site visits for sample collection and only participants with data collected at specified timepoints are reported.

    Time frame: Part 1:Dose escalation (dose levels 1 and 2):Pre-dose and 2, 3, 4, 6, 11 and 24 hours post-dose on Cycle 1 Day 1; pre-dose and 2, 3, 4, 6, 9, 11 and 24 hours post-dose on Cycle 1 Day 8

  5. Sub-study 1: All 3 Parts: Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC) of Venetoclax

    Blood samples were collected at specified timepoints to determine AUC of venetoclax during dose escalation part. Participants missed few scheduled site visits for sample collection and only participants with data collected at specified timepoints are reported.

    Time frame: Part 1:Dose escalation (dose levels 1 and 2):Pre-dose and 2, 3, 4, 6, 11 and 24 hours post-dose on Cycle 1 Day 1

  6. Sub-study 1: All 3 Parts: Maximum Plasma Concentration Observed of Azacitidine

    Blood samples were collected at specified timepoints to determine Cmax of azacitidine during dose escalation part. Participants missed few scheduled site visits for sample collection and only participants with data collected at specified timepoints are reported. The PK samples were not collected at the end of infusion and were therefore outside the protocol-defined time window; consequently, Cmax could not be estimated and N = 0 in IV category. No participants received Azacitidine by SC route, thus N=0 in SC category.

    Time frame: Part 1:Dose escalation (dose levels 1 and 2):Pre-dose, 0.5, 1.5, 2.5, 4.5 and 9.5 hours post-dose on Cycle 1 Day 1

  7. Sub-study 1: All 3 Parts: Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity of Azacitidine

    Blood samples were collected at specified timepoints to determine AUC of azacitidine during dose escalation part. Participants missed few scheduled site visits for sample collection and only participants with data collected at specified timepoints are reported. PK samples were not collected at the end of infusion; therefore, Cmax could not be estimated. In addition, PK samples collected outside the predefined time window resulted in insufficient data to calculate AUC, thus N=0 in IV category. No participants received Azacitidine by SC route, thus N=0 in SC category.

    Time frame: Part 1:Dose escalation (dose levels 1 and 2):Pre-dose, 0.5, 1.5, 2.5, 4.5 and 9.5 hours post-dose on Cycle 1 Day 1

  8. Sub-study 1: All 3 Parts: Number of Participants With Anti-Drug Antibodies (ADAs) Against SAR443579

    Plasma samples were collected to assess the antibodies to SAR443579 during dose escalation part. Treatment-emergent ADA was defined as a participant with at least 1 treatment-induced or treatment-boosted ADA-positive sample at any time during the treatment or follow-up observation period. Non-treatment emergent ADA was defined as participant without any treatment-induced, treatment-boosted ADA-positive or ADA-inconclusive sample during the treatment or follow-up observation period.

    Time frame: Part 1:Dose escalation (dose levels 1 and 2): first dose of study drug administration (Day 1) up to early termination of the study, maximum treatment duration was 31.3 weeks

  9. Sub-study 1: Part 3: Dose Expansion: Composite Complete Remission (CRc) Rate

    The CRc rate was defined as the percentage of participants who had a response of CR, CRh or CRi as best overall response as assessed by the Investigator according to 2022 ELN recommendations for diagnosis and management of AML.

    Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

  10. Sub-study 1: Part 3: Dose Expansion: Overall Response Rate

    The ORR was defined as the percentage of participants who had a response of CR or CRi or CRh or partial remission (PR) or MLFS (morphological leukemia-free state) as best overall response as assessed by the Investigator according to the 2022 ELN criteria.

    Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

  11. Sub-study 1: Part 3: Dose Expansion: Duration of Complete Remission

    Duration of CR was defined as the time interval from the first documented evidence of CR until disease relapse as determined by the Investigator as per 2022 ELN recommendations or death due to any cause, whichever occurred first.

    Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

  12. Sub-study 1: Part 3: Dose Expansion: Duration of Composite Complete Remission

    Duration of CRc was defined as the time interval from first documented evidence of CRc (CR, CRh or CRi) until disease relapse as determined by the Investigator as per 2022 ELN recommendations or death due to any cause, whichever occurred first.

    Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

  13. Sub-study 1: Part 3: Dose Expansion: Duration of Overall Response Rate

    Duration of overall response rate was defined as the time from the first documented evidence of CR or CRi or CRh or PR or MLFS until disease relapse as determined by the Investigator as per 2022 ELN recommendations or death due to any cause, whichever occurred first.

    Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

  14. Sub-study 1: Part 3: Dose Expansion: Alternative Complete Remission Rate

    Alternative CR rate was defined as percentage of participants with alternative CR or CRh as best overall response as assessed by the Investigator.

    Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

  15. Sub-study 1: Part 3: Dose Expansion: Duration of Alternative Complete Remission

    Duration of alternative CR was defined as the time from the first documented evidence of alternative CR or CRh until disease relapse as determined by the Investigator as per 2022 ELN recommendations or death due to any cause, whichever occurred first.

    Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

  16. Sub-study 1: Part 3: Dose Expansion: Event-Free Survival (EFS)

    The EFS was defined as the time interval from the first day of treatment assignment until treatment failure, relapse from remission, or death from any cause, whichever occurred first.

    Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

  17. Sub-study 1: Part 3: Dose Expansion: Overall Survival (OS)

    The OS was defined as time interval from the day of treatment assignment to death from any cause.

    Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

  18. Sub-study 1: Part 3: Dose Expansion: Percentage of Participants With Hematopoietic Stem Cell Transplantation (HSCT)

    The HSCT rate was defined as the percentage of such participants who underwent HSCT through study treatment but before subsequent therapy, among the safety/exposed population.

    Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

  19. Sub-study 1: Part 3: Dose Expansion: Time to Treatment Failure (TTF)

    The TTF was defined as the time from first day of treatment assignment to the first discontinuation for any reason excluding remission, that is, relapsed disease, refractory disease, unacceptable AE, participant preference or death, whichever occurred first.

    Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

  20. Sub-study 1: All 3 Parts: Transfusion Independence (TI) Rate

    The TI rate was defined differently for participants who were transfusion dependent (TD) at baseline and participants who were transfusion independent (TI) at baseline. For subgroup of participants with TD at baseline, the TI rate was defined as the percentage of participants who converted from baseline TD to TI during on treatment period; For subgroup of participants with TI at baseline, the TI rate was defined as the percentage of participants who remained TI during 56-day post baseline period during treatment.

    Time frame: Part 1:Dose escalation (dose levels 1 and 2): From Baseline (Day 1, before 1st dose of study treatment administration) to 56 days post-baseline during treatment period (Maximum exposure duration: 31.3 weeks)

07

Results

Posted Oct 19, 2026
Limitations and caveats
The study was prematurely terminated by the sponsor for non-safety related reasons. Thereby no participants were enrolled in the following parts of sub-study 1: Part 1: Dose escalation-dose level 3 (1.5 mg/kg), Parts 2 and 3; and sub-study 2 (all 3 parts) and these sub-studies parts were not conducted. Thus, related data are not reported in any section of this record. Only results of completed part (sub-study 1: Part 1: Dose escalation-dose level 1 \[0.6 mg/kg\] and 2 \[1 mg/kg\]) are reported.

Participant flow

The study was conducted at 7 sites in 2 countries. A total of 10 participants were screened from 13-Aug-2024 to 03-Apr-2025, of which 3 were screen failures mainly due to not meeting eligibility criteria. A total of 7 participants with CD123-expressing newly diagnosed acute myeloid leukemia (NDAML) who were ineligible for intensive chemotherapy were enrolled. Two sub-studies 1 and 2 were planned with 3 parts in each (Part 1: Dose escalation, Part 2: Dose optimization, Part 3: Dose expansion).

Participant flow — Overall Study
MilestoneSub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + AzacitidineSub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine
Started43
Completed00
Not completed43
Withdrew: Adverse event11
Withdrew: Progressive disease10
Withdrew: Withdrawal by subject10
Withdrew: Other-as reported by the investigator12

Outcome measures

PrimarySub-study 1: Part 1: Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)

DLT=any of the following events during Cycle 1 (first 28 days) using NCI CTCAE v5.0 or ASTCT criteria, whether related or not to study treatment in absence of clear evidence to the contrary, and if not related to disease progression. Hematologic DLTs :toxicities, bone marrow hypocellularity, decreased neutrophils, febrile neutropenia, decreased platelets, anemia (all Grade 4) and Grade 3 thrombocytopenia. Non-hematologic DLTs: organ toxicities or infusion reaction (both Grade 4), Grade 3 infusion reaction lasting \>24 hours, Hy's law cases, Grade 3-4 infection, Grade 3 electrolyte abnormalities or transaminitis elevation, Grade \>=3 toxicities except alopecia, Grade 3 fatigue, asthenia, fever, anorexia, constipation, nausea, vomiting, diarrhea, infection, bleeding, Grade 3 cytokine release syndrome or laboratory abnormalities, Grade 3 or 4 tumor lysis syndrome. Any treatment related toxicity causing \>2-week delay in recovery to baseline/Grade \<=1 or requiring dose reduction/withdrawal.

Time frame:
From Day 1 to Day 28 of Cycle 1 (each cycle was 28 days)
Reported as:
Count of participants · Participants
Sub-study 1: Part 1: Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)
ParticipantsSub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + AzacitidineSub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine
Sub-study 1: Part 1: Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)11
PrimarySub-study 1: Part 2: Dose Optimization: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (SAEs) and Treatment-emergent Adverse Events of Special Interest (AESIs)

An AE was any untoward medical occurrence in participant or clinical study participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was any AE, that at any dose: resulted in death, was life-threatening, required inpatient hospitalization/prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was a medically important event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. The TEAEs were defined as AEs that developed, worsened or became serious after the first administration of study treatment up to 30 days after the last administration of study treatment.

Time frame:
AEs were planned to be collected from first dose of study treatment (Day 1) up to 30 days post last dose of study treatment

No measurements were reported for this outcome.

PrimarySub-study 1: Part 2: Dose Optimization: Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Hematology Parameters

Blood samples were planned to be collected to determine the PCSA in hematology.

Time frame:
Planned to be collected from first dose of study treatment (Day 1) up to 30 days post last dose of study treatment

No measurements were reported for this outcome.

PrimarySub-study 1: Part 2: Dose Optimization: Number of Participants With Potentially Clinically Significant Abnormalities in Clinical Chemistry Parameters

Blood samples were planned to be collected to determine the PCSA in clinical chemistry.

Time frame:
Planned to be collected from first dose of study treatment (Day 1) up to 30 days post last dose of study treatment

No measurements were reported for this outcome.

PrimarySub-study 1: Part 2: Dose Optimization: Complete Remission (CR) Rate

The CR rate was defined as percentage of participants who had a CR determined by the Investigator according to 2022European Leukemia Net (ELN) recommendations for diagnosis and management of AML.

Time frame:
Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenancecycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause,whichever occurred first

No measurements were reported for this outcome.

PrimarySub-study 1: Part 3: Dose Expansion: Complete Remission (CR) Rate

The CR rate was defined as percentage of participants who had a CR determined by the Investigator according to 2022 European Leukemia Net (ELN) recommendations for diagnosis and management of AML.

Time frame:
Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

No measurements were reported for this outcome.

SecondarySub-study 1: Part 1: Dose Escalation and Part 3: Dose Expansion: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TE Serious Adverse Events (TESAEs) and TE Adverse Events of Special Interest (TEAESIs)

An AE was any untoward medical occurrence in participant or clinical study participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was any AE, that at any dose: resulted in death, was life-threatening, required inpatient hospitalization/prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was a medically important event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. TEAEs: AEs that developed, worsened/became serious after first administration of study treatment up to 30 days after last administration of study treatment.

Time frame:
From the first dose of study drug administration (Day 1) up to early termination of the study, maximum treatment duration was 31.3 weeks
Reported as:
Count of participants · Participants
Sub-study 1: Part 1: Dose Escalation and Part 3: Dose Expansion: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TE Serious Adverse Events (TESAEs) and TE Adverse Events of Special Interest (TEAESIs)
ParticipantsSub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + AzacitidineSub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine
TEAEs43
TESAEs32
TEAESIs12
SecondarySub-study 1: Part 3: Dose Expansion: Percentage of Participants With Minimal Residual Disease

The minimal residual disease rate was defined as the percentage of participants with minimal residual disease as defined by 2022 ELN in participants achieving a CR, CR with partial hematologic recovery (CRh) or CR with incomplete hematologic recovery (CRi).

Time frame:
Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

No measurements were reported for this outcome.

SecondarySub-study 1: All 3 Parts: Concentrations Observed at the End of Dosing Period During Repeated Administration (Ctrough) of SAR443579

Blood samples were collected just before treatment administration during repeated dosing to determine the Ctrough of SAR443579 during dose escalation part. Participants missed few scheduled site visits for sample collection and only participants with data collected at specified timepoints are reported.

Time frame:
Part 1:Dose escalation (dose levels 1 and 2): Pre-dose: At Days 1, 8, 15 and 22 of Cycle 1 and Days 8, 15, 22 and 28 of Cycle 2 (each cycle was 28 days)
Reported as:
Mean · nanograms per milliliter (ng/mL)
Sub-study 1: All 3 Parts: Concentrations Observed at the End of Dosing Period During Repeated Administration (Ctrough) of SAR443579
nanograms per milliliter (ng/mL)Sub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + AzacitidineSub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine
Cycle 1 Day 175.000 ± 0.000118.750 ± 58.336
Cycle 1 Day 889.667 ± 25.40375.000
Cycle 1 Day 15427.400 ± 608.4701654.500 ± 1195.718
Cycle 1 Day 22861.650 ± 1100.7533810.000 ± 3577.960
Cycle 2 Day 876.150 ± 1.6262470.500 ± 2431.740
Cycle 2 Day 15121.500 ± 65.7614020.000 ± 4214.356
Cycle 2 Day 22530.000 ± 596.7981800.000
Cycle 2 Day 28135.000—
SecondarySub-study 1: All 3 Parts: Maximum Plasma Concentration Observed (Cmax) of Venetoclax

Blood samples were collected at specified timepoints to determine Cmax of venetoclax during dose escalation part. Participants missed few scheduled site visits for sample collection and only participants with data collected at specified timepoints are reported.

Time frame:
Part 1:Dose escalation (dose levels 1 and 2):Pre-dose and 2, 3, 4, 6, 11 and 24 hours post-dose on Cycle 1 Day 1; pre-dose and 2, 3, 4, 6, 9, 11 and 24 hours post-dose on Cycle 1 Day 8
Reported as:
Mean · ng/mL
Sub-study 1: All 3 Parts: Maximum Plasma Concentration Observed (Cmax) of Venetoclax
ng/mLSub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + AzacitidineSub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine
Cycle 1 Day 1365 ± 211241 ± 287
Cycle 1 Day 81290 ± 6122360 ± 382
SecondarySub-study 1: All 3 Parts: Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC) of Venetoclax

Blood samples were collected at specified timepoints to determine AUC of venetoclax during dose escalation part. Participants missed few scheduled site visits for sample collection and only participants with data collected at specified timepoints are reported.

Time frame:
Part 1:Dose escalation (dose levels 1 and 2):Pre-dose and 2, 3, 4, 6, 11 and 24 hours post-dose on Cycle 1 Day 1
Reported as:
Mean · hour*ng/mL
Sub-study 1: All 3 Parts: Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC) of Venetoclax
hour*ng/mLSub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + AzacitidineSub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine
Sub-study 1: All 3 Parts: Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC) of Venetoclax4870 ± 1970—
SecondarySub-study 1: All 3 Parts: Maximum Plasma Concentration Observed of Azacitidine

Blood samples were collected at specified timepoints to determine Cmax of azacitidine during dose escalation part. Participants missed few scheduled site visits for sample collection and only participants with data collected at specified timepoints are reported. The PK samples were not collected at the end of infusion and were therefore outside the protocol-defined time window; consequently, Cmax could not be estimated and N = 0 in IV category. No participants received Azacitidine by SC route, thus N=0 in SC category.

Time frame:
Part 1:Dose escalation (dose levels 1 and 2):Pre-dose, 0.5, 1.5, 2.5, 4.5 and 9.5 hours post-dose on Cycle 1 Day 1
Reported as:
Mean · ng/mL
Sub-study 1: All 3 Parts: Maximum Plasma Concentration Observed of Azacitidine
ng/mLSub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + AzacitidineSub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine
IV—1530
SC595 ± 66.5—
SecondarySub-study 1: All 3 Parts: Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity of Azacitidine

Blood samples were collected at specified timepoints to determine AUC of azacitidine during dose escalation part. Participants missed few scheduled site visits for sample collection and only participants with data collected at specified timepoints are reported. PK samples were not collected at the end of infusion; therefore, Cmax could not be estimated. In addition, PK samples collected outside the predefined time window resulted in insufficient data to calculate AUC, thus N=0 in IV category. No participants received Azacitidine by SC route, thus N=0 in SC category.

Time frame:
Part 1:Dose escalation (dose levels 1 and 2):Pre-dose, 0.5, 1.5, 2.5, 4.5 and 9.5 hours post-dose on Cycle 1 Day 1
Reported as:
Mean · hour*ng/mL
Sub-study 1: All 3 Parts: Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity of Azacitidine
hour*ng/mLSub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + AzacitidineSub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine
IV—588
SC1040 ± 518—
SecondarySub-study 1: All 3 Parts: Number of Participants With Anti-Drug Antibodies (ADAs) Against SAR443579

Plasma samples were collected to assess the antibodies to SAR443579 during dose escalation part. Treatment-emergent ADA was defined as a participant with at least 1 treatment-induced or treatment-boosted ADA-positive sample at any time during the treatment or follow-up observation period. Non-treatment emergent ADA was defined as participant without any treatment-induced, treatment-boosted ADA-positive or ADA-inconclusive sample during the treatment or follow-up observation period.

Time frame:
Part 1:Dose escalation (dose levels 1 and 2): first dose of study drug administration (Day 1) up to early termination of the study, maximum treatment duration was 31.3 weeks
Reported as:
Count of participants · Participants
Sub-study 1: All 3 Parts: Number of Participants With Anti-Drug Antibodies (ADAs) Against SAR443579
ParticipantsSub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + AzacitidineSub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine
Sub-study 1: All 3 Parts: Number of Participants With Anti-Drug Antibodies (ADAs) Against SAR44357900
SecondarySub-study 1: Part 3: Dose Expansion: Composite Complete Remission (CRc) Rate

The CRc rate was defined as the percentage of participants who had a response of CR, CRh or CRi as best overall response as assessed by the Investigator according to 2022 ELN recommendations for diagnosis and management of AML.

Time frame:
Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

No measurements were reported for this outcome.

SecondarySub-study 1: Part 3: Dose Expansion: Overall Response Rate

The ORR was defined as the percentage of participants who had a response of CR or CRi or CRh or partial remission (PR) or MLFS (morphological leukemia-free state) as best overall response as assessed by the Investigator according to the 2022 ELN criteria.

Time frame:
Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

No measurements were reported for this outcome.

SecondarySub-study 1: Part 3: Dose Expansion: Duration of Complete Remission

Duration of CR was defined as the time interval from the first documented evidence of CR until disease relapse as determined by the Investigator as per 2022 ELN recommendations or death due to any cause, whichever occurred first.

Time frame:
Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

No measurements were reported for this outcome.

SecondarySub-study 1: Part 3: Dose Expansion: Duration of Composite Complete Remission

Duration of CRc was defined as the time interval from first documented evidence of CRc (CR, CRh or CRi) until disease relapse as determined by the Investigator as per 2022 ELN recommendations or death due to any cause, whichever occurred first.

Time frame:
Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

No measurements were reported for this outcome.

SecondarySub-study 1: Part 3: Dose Expansion: Duration of Overall Response Rate

Duration of overall response rate was defined as the time from the first documented evidence of CR or CRi or CRh or PR or MLFS until disease relapse as determined by the Investigator as per 2022 ELN recommendations or death due to any cause, whichever occurred first.

Time frame:
Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

No measurements were reported for this outcome.

SecondarySub-study 1: Part 3: Dose Expansion: Alternative Complete Remission Rate

Alternative CR rate was defined as percentage of participants with alternative CR or CRh as best overall response as assessed by the Investigator.

Time frame:
Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

No measurements were reported for this outcome.

SecondarySub-study 1: Part 3: Dose Expansion: Duration of Alternative Complete Remission

Duration of alternative CR was defined as the time from the first documented evidence of alternative CR or CRh until disease relapse as determined by the Investigator as per 2022 ELN recommendations or death due to any cause, whichever occurred first.

Time frame:
Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

No measurements were reported for this outcome.

SecondarySub-study 1: Part 3: Dose Expansion: Event-Free Survival (EFS)

The EFS was defined as the time interval from the first day of treatment assignment until treatment failure, relapse from remission, or death from any cause, whichever occurred first.

Time frame:
Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

No measurements were reported for this outcome.

SecondarySub-study 1: Part 3: Dose Expansion: Overall Survival (OS)

The OS was defined as time interval from the day of treatment assignment to death from any cause.

Time frame:
Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

No measurements were reported for this outcome.

SecondarySub-study 1: Part 3: Dose Expansion: Percentage of Participants With Hematopoietic Stem Cell Transplantation (HSCT)

The HSCT rate was defined as the percentage of such participants who underwent HSCT through study treatment but before subsequent therapy, among the safety/exposed population.

Time frame:
Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

No measurements were reported for this outcome.

SecondarySub-study 1: Part 3: Dose Expansion: Time to Treatment Failure (TTF)

The TTF was defined as the time from first day of treatment assignment to the first discontinuation for any reason excluding remission, that is, relapsed disease, refractory disease, unacceptable AE, participant preference or death, whichever occurred first.

Time frame:
Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first

No measurements were reported for this outcome.

SecondarySub-study 1: All 3 Parts: Transfusion Independence (TI) Rate

The TI rate was defined differently for participants who were transfusion dependent (TD) at baseline and participants who were transfusion independent (TI) at baseline. For subgroup of participants with TD at baseline, the TI rate was defined as the percentage of participants who converted from baseline TD to TI during on treatment period; For subgroup of participants with TI at baseline, the TI rate was defined as the percentage of participants who remained TI during 56-day post baseline period during treatment.

Time frame:
Part 1:Dose escalation (dose levels 1 and 2): From Baseline (Day 1, before 1st dose of study treatment administration) to 56 days post-baseline during treatment period (Maximum exposure duration: 31.3 weeks)
Reported as:
Number · percentage of participants
Sub-study 1: All 3 Parts: Transfusion Independence (TI) Rate
percentage of participantsSub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + AzacitidineSub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine
Rate of conversion from TD to TI0 (0.0 to 77.6)0 (0.0 to 63.2)
Rate of participants who were TI at baseline and remained independent during treatment period0 (0.0 to 77.6)—

Adverse events

Collected over SAEs and other AEs were collected from first dose of study drug administration (Day 1) up to early termination of the study, maximum treatment duration was 31.3 weeks for sub-study 1: Part 1: Dose Escalation: DL 1 and 2. All-cause mortality was collected from the first dose of study drug administration (Day 1) up to the longest duration of survival follow up for each participant; maximum duration being 51 weeks 4 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + Azacitidine1/4 (25%)3/4 (75%)4/4 (100%)
Sub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine2/3 (66.7%)2/3 (66.7%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventSub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + AzacitidineSub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine
Infusion Related ReactionInjury, poisoning and procedural complications2/41/3
SepsisInfections and infestations1/41/3
Febrile NeutropeniaBlood and lymphatic system disorders0/41/3
Tumour Lysis SyndromeMetabolism and nutrition disorders0/41/3
Pleural EffusionRespiratory, thoracic and mediastinal disorders0/41/3
PyrexiaGeneral disorders0/41/3
Most frequent other events
Showing 10 of 56
Most frequent other events
EventSub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + AzacitidineSub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine
EpistaxisRespiratory, thoracic and mediastinal disorders2/42/3
DiarrhoeaGastrointestinal disorders2/42/3
Oedema PeripheralGeneral disorders0/42/3
Infusion Related ReactionInjury, poisoning and procedural complications2/42/3
Decreased AppetiteMetabolism and nutrition disorders2/41/3
ConstipationGastrointestinal disorders2/41/3
Neutrophil Count DecreasedInvestigations2/41/3
Platelet Count DecreasedInvestigations2/41/3
GingivitisInfections and infestations0/41/3
PneumoniaInfections and infestations0/41/3

Baseline characteristics

The exposed population included all screened participants who had taken at least 1 dose of study treatment regardless of the amount of study treatment administered.

Age, Continuous
Age, Continuous(years)Sub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + AzacitidineSub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + AzacitidineTotal
Mean78.3 ± 3.966.7 ± 4.273.3 ± 7.2
Sex: Female, Male
Sex: Female, Male(Participants)Sub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + AzacitidineSub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + AzacitidineTotal
Female101
Male336
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + AzacitidineSub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + AzacitidineTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American000
White325
More than one race000
Unknown or Not Reported000
08

Study locations

7 sites
  • City of Hope National Medical Center- Site Number : 8400003
    Duarte, California 91010, United States
  • Montefiore Medical Center - Moses Campus- Site Number : 8400004
    The Bronx, New York 10467, United States
  • The Ohio State University Wexner Medical Center - Ohio State Outpatient Care Upper Arlington- Site Number : 8400001
    Columbus, Ohio 43221, United States
  • Oregon Health and Science University- Site Number : 8400006
    Portland, Oregon 97239, United States
  • The University of Texas MD Anderson Cancer Center- Site Number : 8400008
    Houston, Texas 77030, United States
  • Investigational Site Number : 0360002
    Wollongong, New South Wales 2500, Australia
  • Investigational Site Number : 0360001
    Melbourne, Victoria 3000, Australia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Aug 2025, 11 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2024
First posted
Jul 18, 2024
StartActual
Aug 13, 2024
Primary completionActual
Aug 8, 2025
CompletionActual
Aug 8, 2025
Results first posted
Oct 19, 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 19, 2026
Eligibility
3 inclusion criteria edited; 7 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedIneligible for intensive chemotherapy. Ineligible for intensive chemotherapy iswas defined by the following criteria:
  • EditedSubjectParticipant with an Eastern Cooperative Oncology Group (ECOG) performance status as follows:
  • EditedSubjectParticipant with adequate liver function demonstrated by the following:
Exclusion criteria
  • EditedAny clinically significant, uncontrolled medical conditions (including any serious active systemic infection that iswas not controlled)
  • EditedHBV as determined by positive test for hepatitis B surface antigen (HBsAg) and/or HBV DNA. Participant who teststested positive for anti-hepatitis B core (HBc) antigen IgG (with or without testing positive for anti-HBs), but teststested negative for HBsAg and HBV DNA, iswas eligible.
  • EditedA participant who teststested positive for anti-HCV antibodies and hashad undetectable HCV RNA without receiving antiviral treatment for HCV iswas eligible.
  • EditedActive, known, or suspected clinically significant autoimmune disease that hashad required systemic treatment in the past 2 years prior to first IMP administration, except controlled by replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc)
  • EditedMedical conditions requiring treatment with medications with narrow therapeutic index that arewere substrates of CYP enzymes and that cannotcould not be closely monitored to allow for dose adjustment.
  • EditedSubject hasParticipant had received treatment with at least one of the following:
  • EditedThe above information iswas not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Oct 19, 2026
Primary outcomes
1 edited, 5 added, 3 removed
What changed in the outcomes
  • EditedSub-study 1: Part 2: Dose Optimization: Number of participants with adverse eventsParticipants With Treatment-emergent Adverse Events (AEsTEAEs)/serious adverse events, Treatment-emergent Serious Adverse Events (SAEs)/adverse events and Treatment-emergent Adverse Events of special interestSpecial Interest (AESIs), laboratory abnormalitiesTime frame: Day 1 to 30 days after the last administration of study treatment → AEs were planned to be collected from first dose of study treatment (Day 1) up to 30 days post last dose of study treatment
  • AddedSub-study 1: Part 1: Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: From Day 1 to Day 28 of Cycle 1 (each cycle was 28 days)
  • AddedSub-study 1: Part 2: Dose Optimization: Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Hematology ParametersTime frame: Planned to be collected from first dose of study treatment (Day 1) up to 30 days post last dose of study treatment
  • AddedSub-study 1: Part 2: Dose Optimization: Number of Participants With Potentially Clinically Significant Abnormalities in Clinical Chemistry ParametersTime frame: Planned to be collected from first dose of study treatment (Day 1) up to 30 days post last dose of study treatment
  • AddedSub-study 1: Part 2: Dose Optimization: Complete Remission (CR) RateTime frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenancecycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause,whichever occurred first
  • AddedSub-study 1: Part 3: Dose Expansion: Complete Remission (CR) RateTime frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
  • RemovedSubstudy 01: Incidence of dose limiting toxicities (DLTs) (escalation part)Time frame: Day 1 to Day 28
  • RemovedSubstudy 01: Complete Remission (CR) rate (optimization part)Time frame: Day 1 to 30 days after the last administration of study treatment
  • RemovedSubstudy 01: Complete Remission (CR) rate (expansion part)Time frame: Day 1 up to 6 months
Oct 19, 2026
Documents
Secondary outcomes
6 edited, 14 added, 10 removed, 5 more
What changed in the outcomes
  • EditedSub-study 1: Part 1: Dose Escalation and Part 3: Dose Expansion: Number of participants with treatment emergent adverse eventsParticipants With Treatment-Emergent Adverse Events (TEAEs), serious adverse eventsTE Serious Adverse Events (SAEs), adverse events of special interest (AESIsTESAEs) and clinically significant laboratory abnormalitiesTE Adverse Events of Special Interest (expansion partTEAESIs)Time frame: Day 1 to 30 days after the last administration of study treatment → From the first dose of study drug administration (Day 1) up to early termination of the study, maximum treatment duration was 31.3 weeks
  • EditedIncidenceSub-study 1: All 3 Parts: Number of antiParticipants With Anti-drug anti bodyDrug Antibodies (ADAADAs) againstAgainst SAR443579Time frame: Day 1 to 30 days after the last administration of study treatment → Part 1:Dose escalation (dose levels 1 and 2): first dose of study drug administration (Day 1) up to early termination of the study, maximum treatment duration was 31.3 weeks
  • EditedSubstudy 01Sub-study 1: Part 3: Dose Expansion: Percentage of participants withParticipants With Minimal residual disease (expansion part)Residual DiseaseTime frame: Day 1 up to 6 months → Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
  • EditedSubstudy 01Sub-study 1: Part 3: Dose Expansion: Composite Complete Remission (CRc) rateRateTime frame: Day 1 up to 6 months → Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
  • EditedSubstudy 01Sub-study 1: Part 3: Dose Expansion: Event-free survivalFree Survival (EFS) (expansion part)Time frame: Day 1 up to 24 months after the last administration from study treatment → Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
  • EditedSubstudy 01Sub-study 1: Part 3: Dose Expansion: Time to treatment failureTreatment Failure (TTF) (expansion part)Time frame: Day 1 up to 24 months after the last administration from study treatment → Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
  • AddedSub-study 1: All 3 Parts: Concentrations Observed at the End of Dosing Period During Repeated Administration (Ctrough) of SAR443579Time frame: Part 1:Dose escalation (dose levels 1 and 2): Pre-dose: At Days 1, 8, 15 and 22 of Cycle 1 and Days 8, 15, 22 and 28 of Cycle 2 (each cycle was 28 days)
  • AddedSub-study 1: All 3 Parts: Maximum Plasma Concentration Observed (Cmax) of VenetoclaxTime frame: Part 1:Dose escalation (dose levels 1 and 2):Pre-dose and 2, 3, 4, 6, 11 and 24 hours post-dose on Cycle 1 Day 1; pre-dose and 2, 3, 4, 6, 9, 11 and 24 hours post-dose on Cycle 1 Day 8
  • AddedSub-study 1: All 3 Parts: Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC) of VenetoclaxTime frame: Part 1:Dose escalation (dose levels 1 and 2):Pre-dose and 2, 3, 4, 6, 11 and 24 hours post-dose on Cycle 1 Day 1
  • AddedSub-study 1: All 3 Parts: Maximum Plasma Concentration Observed of AzacitidineTime frame: Part 1:Dose escalation (dose levels 1 and 2):Pre-dose, 0.5, 1.5, 2.5, 4.5 and 9.5 hours post-dose on Cycle 1 Day 1
  • AddedSub-study 1: All 3 Parts: Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity of AzacitidineTime frame: Part 1:Dose escalation (dose levels 1 and 2):Pre-dose, 0.5, 1.5, 2.5, 4.5 and 9.5 hours post-dose on Cycle 1 Day 1
  • AddedSub-study 1: Part 3: Dose Expansion: Overall Response RateTime frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
  • AddedSub-study 1: Part 3: Dose Expansion: Duration of Complete RemissionTime frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
  • AddedSub-study 1: Part 3: Dose Expansion: Duration of Composite Complete RemissionTime frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
  • AddedSub-study 1: Part 3: Dose Expansion: Duration of Overall Response RateTime frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
  • AddedSub-study 1: Part 3: Dose Expansion: Alternative Complete Remission RateTime frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
  • AddedSub-study 1: Part 3: Dose Expansion: Duration of Alternative Complete RemissionTime frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
  • AddedSub-study 1: Part 3: Dose Expansion: Overall Survival (OS)Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
  • AddedSub-study 1: Part 3: Dose Expansion: Percentage of Participants With Hematopoietic Stem Cell Transplantation (HSCT)Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
  • AddedSub-study 1: All 3 Parts: Transfusion Independence (TI) RateTime frame: Part 1:Dose escalation (dose levels 1 and 2): From Baseline (Day 1, before 1st dose of study treatment administration) to 56 days post-baseline during treatment period (Maximum exposure duration: 31.3 weeks)
  • RemovedSubstudy 01: Pharmacokinetic (PK) parameter of SAR443579: CtroughTime frame: Day 1 up to 10 cycles (each cycle 28 days)
  • RemovedSubstudy 01: PK parameter of venetoclax: CmaxTime frame: Day 1 to Day 28
  • RemovedSubstudy 01: PK parameter of azacitidine: CmaxTime frame: Day 1 to Day 28
  • RemovedSubstudy 01: PK parameter of venetoclax: AUCTime frame: Day 1 to Day 28
  • RemovedSubstudy 01: PK parameter of azacitidine: AUCTime frame: Day 1 to Day 28
  • RemovedSubstudy 01: Overall response rate (expansion part)Time frame: Day 1 up to 6 months
  • RemovedSubstudy 01: Duration of CR (expansion part)Time frame: Day 1 up to 24 months after the last administration from study treatment
  • RemovedSubstudy 01: Duration of CRc (expansion part)Time frame: Day 1 up to 24 months after the last administration from study treatment
  • RemovedSubstudy 01: Duration of overall response (expansion part)Time frame: Day 1 up to 24 months after the last administration from study treatment
  • RemovedSubstudy 01: Alternative CR rate (expansion part)Time frame: Day 1 up to 6 months
  • …and 5 more, on the record history on ClinicalTrials.gov ↗
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Results posted
    Eligibility 3 inclusion criteria edited; 7 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedIneligible for intensive chemotherapy. Ineligible for intensive chemotherapy iswas defined by the following criteria:
    • EditedSubjectParticipant with an Eastern Cooperative Oncology Group (ECOG) performance status as follows:
    • EditedSubjectParticipant with adequate liver function demonstrated by the following:
    Exclusion criteria
    • EditedAny clinically significant, uncontrolled medical conditions (including any serious active systemic infection that iswas not controlled)
    • EditedHBV as determined by positive test for hepatitis B surface antigen (HBsAg) and/or HBV DNA. Participant who teststested positive for anti-hepatitis B core (HBc) antigen IgG (with or without testing positive for anti-HBs), but teststested negative for HBsAg and HBV DNA, iswas eligible.
    • EditedA participant who teststested positive for anti-HCV antibodies and hashad undetectable HCV RNA without receiving antiviral treatment for HCV iswas eligible.
    • EditedActive, known, or suspected clinically significant autoimmune disease that hashad required systemic treatment in the past 2 years prior to first IMP administration, except controlled by replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc)
    • EditedMedical conditions requiring treatment with medications with narrow therapeutic index that arewere substrates of CYP enzymes and that cannotcould not be closely monitored to allow for dose adjustment.
    • EditedSubject hasParticipant had received treatment with at least one of the following:
    • EditedThe above information iswas not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
    Primary outcomes 1 edited, 5 added, 3 removed
    What changed in the outcomes
    • EditedSub-study 1: Part 2: Dose Optimization: Number of participants with adverse eventsParticipants With Treatment-emergent Adverse Events (AEsTEAEs)/serious adverse events, Treatment-emergent Serious Adverse Events (SAEs)/adverse events and Treatment-emergent Adverse Events of special interestSpecial Interest (AESIs), laboratory abnormalitiesTime frame: Day 1 to 30 days after the last administration of study treatment → AEs were planned to be collected from first dose of study treatment (Day 1) up to 30 days post last dose of study treatment
    • AddedSub-study 1: Part 1: Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: From Day 1 to Day 28 of Cycle 1 (each cycle was 28 days)
    • AddedSub-study 1: Part 2: Dose Optimization: Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Hematology ParametersTime frame: Planned to be collected from first dose of study treatment (Day 1) up to 30 days post last dose of study treatment
    • AddedSub-study 1: Part 2: Dose Optimization: Number of Participants With Potentially Clinically Significant Abnormalities in Clinical Chemistry ParametersTime frame: Planned to be collected from first dose of study treatment (Day 1) up to 30 days post last dose of study treatment
    • AddedSub-study 1: Part 2: Dose Optimization: Complete Remission (CR) RateTime frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenancecycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause,whichever occurred first
    • AddedSub-study 1: Part 3: Dose Expansion: Complete Remission (CR) RateTime frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
    • RemovedSubstudy 01: Incidence of dose limiting toxicities (DLTs) (escalation part)Time frame: Day 1 to Day 28
    • RemovedSubstudy 01: Complete Remission (CR) rate (optimization part)Time frame: Day 1 to 30 days after the last administration of study treatment
    • RemovedSubstudy 01: Complete Remission (CR) rate (expansion part)Time frame: Day 1 up to 6 months
    Secondary outcomes 6 edited, 14 added, 10 removed, 5 more
    What changed in the outcomes
    • EditedSub-study 1: Part 1: Dose Escalation and Part 3: Dose Expansion: Number of participants with treatment emergent adverse eventsParticipants With Treatment-Emergent Adverse Events (TEAEs), serious adverse eventsTE Serious Adverse Events (SAEs), adverse events of special interest (AESIsTESAEs) and clinically significant laboratory abnormalitiesTE Adverse Events of Special Interest (expansion partTEAESIs)Time frame: Day 1 to 30 days after the last administration of study treatment → From the first dose of study drug administration (Day 1) up to early termination of the study, maximum treatment duration was 31.3 weeks
    • EditedIncidenceSub-study 1: All 3 Parts: Number of antiParticipants With Anti-drug anti bodyDrug Antibodies (ADAADAs) againstAgainst SAR443579Time frame: Day 1 to 30 days after the last administration of study treatment → Part 1:Dose escalation (dose levels 1 and 2): first dose of study drug administration (Day 1) up to early termination of the study, maximum treatment duration was 31.3 weeks
    • EditedSubstudy 01Sub-study 1: Part 3: Dose Expansion: Percentage of participants withParticipants With Minimal residual disease (expansion part)Residual DiseaseTime frame: Day 1 up to 6 months → Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
    • EditedSubstudy 01Sub-study 1: Part 3: Dose Expansion: Composite Complete Remission (CRc) rateRateTime frame: Day 1 up to 6 months → Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
    • EditedSubstudy 01Sub-study 1: Part 3: Dose Expansion: Event-free survivalFree Survival (EFS) (expansion part)Time frame: Day 1 up to 24 months after the last administration from study treatment → Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
    • EditedSubstudy 01Sub-study 1: Part 3: Dose Expansion: Time to treatment failureTreatment Failure (TTF) (expansion part)Time frame: Day 1 up to 24 months after the last administration from study treatment → Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
    • AddedSub-study 1: All 3 Parts: Concentrations Observed at the End of Dosing Period During Repeated Administration (Ctrough) of SAR443579Time frame: Part 1:Dose escalation (dose levels 1 and 2): Pre-dose: At Days 1, 8, 15 and 22 of Cycle 1 and Days 8, 15, 22 and 28 of Cycle 2 (each cycle was 28 days)
    • AddedSub-study 1: All 3 Parts: Maximum Plasma Concentration Observed (Cmax) of VenetoclaxTime frame: Part 1:Dose escalation (dose levels 1 and 2):Pre-dose and 2, 3, 4, 6, 11 and 24 hours post-dose on Cycle 1 Day 1; pre-dose and 2, 3, 4, 6, 9, 11 and 24 hours post-dose on Cycle 1 Day 8
    • AddedSub-study 1: All 3 Parts: Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC) of VenetoclaxTime frame: Part 1:Dose escalation (dose levels 1 and 2):Pre-dose and 2, 3, 4, 6, 11 and 24 hours post-dose on Cycle 1 Day 1
    • AddedSub-study 1: All 3 Parts: Maximum Plasma Concentration Observed of AzacitidineTime frame: Part 1:Dose escalation (dose levels 1 and 2):Pre-dose, 0.5, 1.5, 2.5, 4.5 and 9.5 hours post-dose on Cycle 1 Day 1
    • AddedSub-study 1: All 3 Parts: Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity of AzacitidineTime frame: Part 1:Dose escalation (dose levels 1 and 2):Pre-dose, 0.5, 1.5, 2.5, 4.5 and 9.5 hours post-dose on Cycle 1 Day 1
    • AddedSub-study 1: Part 3: Dose Expansion: Overall Response RateTime frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
    • AddedSub-study 1: Part 3: Dose Expansion: Duration of Complete RemissionTime frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
    • AddedSub-study 1: Part 3: Dose Expansion: Duration of Composite Complete RemissionTime frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
    • AddedSub-study 1: Part 3: Dose Expansion: Duration of Overall Response RateTime frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
    • AddedSub-study 1: Part 3: Dose Expansion: Alternative Complete Remission RateTime frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
    • AddedSub-study 1: Part 3: Dose Expansion: Duration of Alternative Complete RemissionTime frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
    • AddedSub-study 1: Part 3: Dose Expansion: Overall Survival (OS)Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
    • AddedSub-study 1: Part 3: Dose Expansion: Percentage of Participants With Hematopoietic Stem Cell Transplantation (HSCT)Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
    • AddedSub-study 1: All 3 Parts: Transfusion Independence (TI) RateTime frame: Part 1:Dose escalation (dose levels 1 and 2): From Baseline (Day 1, before 1st dose of study treatment administration) to 56 days post-baseline during treatment period (Maximum exposure duration: 31.3 weeks)
    • RemovedSubstudy 01: Pharmacokinetic (PK) parameter of SAR443579: CtroughTime frame: Day 1 up to 10 cycles (each cycle 28 days)
    • RemovedSubstudy 01: PK parameter of venetoclax: CmaxTime frame: Day 1 to Day 28
    • RemovedSubstudy 01: PK parameter of azacitidine: CmaxTime frame: Day 1 to Day 28
    • RemovedSubstudy 01: PK parameter of venetoclax: AUCTime frame: Day 1 to Day 28
    • RemovedSubstudy 01: PK parameter of azacitidine: AUCTime frame: Day 1 to Day 28
    • RemovedSubstudy 01: Overall response rate (expansion part)Time frame: Day 1 up to 6 months
    • RemovedSubstudy 01: Duration of CR (expansion part)Time frame: Day 1 up to 24 months after the last administration from study treatment
    • RemovedSubstudy 01: Duration of CRc (expansion part)Time frame: Day 1 up to 24 months after the last administration from study treatment
    • RemovedSubstudy 01: Duration of overall response (expansion part)Time frame: Day 1 up to 24 months after the last administration from study treatment
    • RemovedSubstudy 01: Alternative CR rate (expansion part)Time frame: Day 1 up to 6 months
    • …and 5 more, on the record history on ClinicalTrials.gov ↗
    + 4 other changes: identifiers, verification date, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06508489
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jul 18, 2024
Start date
Aug 13, 2024
Primary completion
Aug 8, 2025
Completion
Aug 8, 2025
Results posted
Oct 19, 2026
Last update
Oct 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion